Literature DB >> 12861964

Selection of the first-time dose in humans: comparison of different approaches based on interspecies scaling of clearance.

Iftekhar Mahmood1, Martin David Green, J Edward Fisher.   

Abstract

The authors describe four approaches to selecting a safe starting dose for humans in clinical drug trials based on interspecies scaling of clearance. Human clearance was predicted by scaling for 10 example drugs for which animal clearance values were available in the literature. The predicted human clearance values were then used to select the estimated starting dose in humans. These doses were then compared with the actual doses given to humans during clinical trials. All four approaches used to estimate the first-time dose in humans provided values that were within the dose range given to humans from Phases I to III. This work demonstrates that animal pharmacokinetic data can be used to estimate a suitable human starting dose, provided the data have been obtained from a dose that produces no adverse effects.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12861964

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  14 in total

Review 1.  Applications of human pharmacokinetic prediction in first-in-human dose estimation.

Authors:  Peng Zou; Yanke Yu; Nan Zheng; Yongsheng Yang; Hayley J Paholak; Lawrence X Yu; Duxin Sun
Journal:  AAPS J       Date:  2012-03-10       Impact factor: 4.009

2.  Interspecies scaling for the prediction of drug clearance in children: application of maximum lifespan potential and an empirical correction factor.

Authors:  Iftekhar Mahmood
Journal:  Clin Pharmacokinet       Date:  2010-07       Impact factor: 6.447

3.  Challenges in conducting clinical trials in children: approaches for improving performance.

Authors:  Steven E Kern
Journal:  Expert Rev Clin Pharmacol       Date:  2009-11-01       Impact factor: 5.045

4.  Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors.

Authors:  Elaine T Lam; Sanjay Goel; Larry J Schaaf; Gillian F Cropp; Alison L Hannah; Yiqing Zhou; Barbara McCracken; Brandi I Haley; Robert G Johnson; Sridhar Mani; Miguel A Villalona-Calero
Journal:  Cancer Chemother Pharmacol       Date:  2011-08-27       Impact factor: 3.333

5.  Risk assessment in extrapolation of pharmacokinetics from preclinical data to humans.

Authors:  Zvi Teitelbaum; Thierry Lave; Jan Freijer; Adam F Cohen
Journal:  Clin Pharmacokinet       Date:  2010-09       Impact factor: 6.447

Review 6.  Modeling, simulation, and translation framework for the preclinical development of monoclonal antibodies.

Authors:  Kenneth T Luu; Eugenia Kraynov; Bing Kuang; Paolo Vicini; Wei-Zhu Zhong
Journal:  AAPS J       Date:  2013-02-14       Impact factor: 4.009

7.  Prediction of Antimalarial Drug Clearance in Children: A Comparison of Three Different Interspecies Scaling Methods.

Authors:  Iftekhar Mahmood; Anna Cheng; Edward Brauer; Rita Humeniuk
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-12       Impact factor: 2.441

Review 8.  Metabotropic glutamate receptor modulation, translational methods, and biomarkers: relationships with anxiety.

Authors:  R E Nordquist; T Steckler; J G Wettstein; C Mackie; W Spooren
Journal:  Psychopharmacology (Berl)       Date:  2008-03-06       Impact factor: 4.530

9.  Pharmacokinetics and interspecies allometric scaling of ST-246, an oral antiviral therapeutic for treatment of orthopoxvirus infection.

Authors:  Adams Amantana; Yali Chen; Shanthakumar R Tyavanagimatt; Kevin F Jones; Robert Jordan; Jarasvech Chinsangaram; Tove C Bolken; Janet M Leeds; Dennis E Hruby
Journal:  PLoS One       Date:  2013-04-18       Impact factor: 3.752

10.  Detrimental effects of tropisetron on permanent ischemic stroke in the rat.

Authors:  Eduardo Candelario-Jalil; Eduardo Muñoz; Bernd L Fiebich
Journal:  BMC Neurosci       Date:  2008-02-06       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.